Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
s1KTjY2J7JGXyKh5
Écouter
